Bonesupport Holding AB

Bonesupport Holding AB

BONEX · ST · Healthcare / Medical Instruments & Supplies

321.20SEK+4.40 (+1.39%)

Price History

Full chart

Market Stats

Previous Close316.80
Open315.80
Day Range315.60 – 322.80
52-Week Range165.00 – 303.80
Volume164.67K
Market Cap14.53B
P/E (TTM)69.35
Forward P/E0.00
EPS3.21
Dividend Yield0.00%
Beta0.48
50-Day Avg222.27
200-Day Avg212.65

About

Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally. The company offers CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; and CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also provides CERAMENT Bead Tray, an adjunctive local delivery option for surgeons desiring targeted delivery to osseous defects and for dead space management. Bonesupport Holding AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Torbjorn Skold
  • Employees171
  • HeadquartersScheelevägen 19, Lund, Sweden, 223 70, Sweden
  • Websitehttps://www.bonesupport.com

Leadership

  • Mr. Torbjorn SkoldChief Executive Officer · b. 1977
  • Mr. Håkan JohanssonChief Financial Officer · b. 1963
  • Mr. Michael Wrang MortensenExecutive Vice President of Global R&D and Operations · b. 1975
  • Ms. Annelie Aava ViknerExecutive Vice President of Global Marketing · b. 1971
  • Ms. Helena L. BrandtExecutive Vice President of Human Resources · b. 1965
  • Dr. Michael Diefenbeck M.D., Ph.D.Executive VP of Medical & Clinical Affairs and Chief Medical Officer · b. 1974
  • Mr. Fergus MacLeodGM & Executive VP of Commercial Operations of EUROW · b. 1970
  • Mr. Michael RothGM & Executive VP of Commercial Operations of US · b. 1963
  • Ms. Anna StegmarkExecutive Vice President of Quality Management & Regulatory Affairs · b. 1980

Financials

Income Statement

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue40.96M61.76M104.60M129.30M96.62M155.46M180.86M212.88M328.82M591.08M898.73M1.17B
Growth (%)-+50.77%+69.38%+23.62%-25.27%+60.90%+16.34%+17.71%+54.46%+79.76%+52.05%+30.70%
Cost of Revenue6.37M9.51M16.31M16.87M15.16M19.59M19.26M22.86M28.04M50.16M66.48M87.33M
Gross Profit34.59M52.25M88.29M112.43M81.47M135.88M161.60M190.03M300.78M540.92M832.25M1.09B
Gross Margin84.44%84.61%84.41%86.95%84.31%87.40%89.35%89.26%91.47%91.51%92.60%92.57%
Operating Expense73.89M106.15M177.03M211.72M255.87M293.59M257.80M270.69M365.31M526.99M666.10M810.66M
Operating Income-39.30M-53.91M-88.75M-99.28M-174.40M-157.72M-96.19M-80.67M-64.53M13.93M166.15M276.67M
Operating Margin-95.95%-87.29%-84.84%-76.79%-180.50%-101.45%-53.19%-37.89%-19.63%2.36%18.49%23.55%
EBITDA-43.35M-49.71M-92.24M-101.55M-172.97M-150.87M-90.91M-72.39M-54.34M28.94M185.75M288.25M
EBITDA Margin-105.83%-80.49%-88.19%-78.54%-179.02%-97.05%-50.27%-34.01%-16.53%4.90%20.67%24.54%
Net Income-51.06M-59.55M-110.19M-128.87M-176.41M-161.06M-101.41M-85.53M-68.17M245.02M133.75M142.15M
Net Income Margin-124.67%-96.44%-105.35%-99.67%-182.57%-103.60%-56.07%-40.18%-20.73%41.45%14.88%12.10%
R&D17.02M19.00M38.23M60.64M66.06M68.88M57.90M53.01M53.09M57.10M76.01M91.40M
R&D as % of Total Revenue41.55%30.77%36.55%46.90%68.37%44.31%32.01%24.90%16.15%9.66%8.46%7.78%
Interest Expense8.25M9.49M17.11M25.93M1.07M275.00K445.00K1.17M970.00K3.12M2.29M3.34M
Interest Expense % of Total Revenue20.14%15.37%16.36%20.05%1.11%0.18%0.25%0.55%0.29%0.53%0.26%0.28%

Balance Sheet

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets45.62M111.63M188.81M596.68M326.14M196.33M465.22M343.92M371.82M688.82M879.69M1.04B
Total Liabilities89.14M91.31M154.50M145.90M47.61M72.02M66.32M78.22M102.89M143.64M152.23M168.88M
Total Equity-43.52M20.33M34.30M450.79M278.53M124.31M398.90M265.70M268.93M545.18M727.46M867.26M
Cash18.39M68.88M141.50M533.37M261.47M92.06M353.74M206.46M201.28M167.35M227.00M377.99M
Total Debt66.80M62.89M109.70M98.62M-10.38M10.48M21.42M17.45M17.48M14.59M11.68M
Net Debt48.41M-5.99M-31.80M-434.75M-261.47M-81.68M-343.26M-185.04M-183.83M-149.87M-212.41M-366.31M

Cash Flow

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-45.92M-65.29M-81.93M-107.53M-171.63M-163.83M-100.28M-83.42M-46.98M-18.26M65.76M221.30M
Investing Cash Flow-755.00K-1.31M-1.37M-4.69M-2.72M-4.42M-2.66M-3.42M-3.28M-6.06M-6.26M-5.88M
Financing Cash Flow35.11M116.80M155.13M504.83M-98.79M-1.82M365.34M-61.56M42.78M-6.70M-4.81M-58.04M
Capital Expenditure1.06M1.43M1.37M4.61M2.61M4.42M2.66M3.42M1.96M6.06M5.84M5.20M
Free Cash Flow-46.99M-66.72M-83.31M-112.14M-174.23M-168.25M-102.93M-86.84M-48.94M-24.32M59.92M216.11M
Dividends Paid-------5.51M----
FCF to OCF102.32%102.19%101.68%104.29%101.52%102.70%102.65%104.09%104.17%133.19%91.12%97.65%
Dividend Paid to FCF--------6.34%----

Earnings

Report DateAug 17, 2017Nov 2, 2017Feb 20, 2018May 4, 2018Jul 26, 2018Nov 7, 2018Feb 27, 2019May 2, 2019Jul 25, 2019Nov 7, 2019Feb 26, 2020May 8, 2020Jul 17, 2020Nov 5, 2020Feb 17, 2021May 6, 2021Jul 15, 2021Nov 4, 2021Feb 17, 2022May 4, 2022Jul 14, 2022Oct 27, 2022Feb 16, 2023Apr 27, 2023Jul 13, 2023Oct 26, 2023Feb 15, 2024Apr 25, 2024Jul 11, 2024Oct 24, 2024Feb 25, 2025Apr 24, 2025Jul 15, 2025Oct 23, 2025Feb 24, 2026Apr 22, 2026Jul 15, 2026Oct 22, 2026
EPS Estimate--------------------------------0.900.770.910.971.151.25
EPS Actual-0.78-0.47-1.03-0.67-0.75-1.13-0.88-0.75-0.93-0.64-0.79-0.56-0.41-0.33-0.43-0.32-0.42-0.22-0.38-0.25-0.25-0.23-0.320.000.083.470.160.330.410.460.810.160.910.620.660.801.41-
Surprise--------------------------------1.11%-19.48%-27.47%-17.53%22.61%-
TimingPre-marketPre-marketPre-market--Pre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap14.53B
Enterprise Value13.53B
Trailing P/E69.35
Forward P/E0.00
Price / Sales11.29
Price / Book14.69
EPS3.21
Book Value14.42
Revenue (TTM)1.29B
Gross Profit (TTM)1.18B
EBITDA311.52M
Profit Margin16.63%
Operating Margin23.92%
Return on Equity24.50%
Return on Assets18.58%
Shares Outstanding65.25M
Shares Float58.85M
Beta0.48
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%